Overview
CellVec is a GMP-certified Contract Development and Manufacturing Organisation (CDMO) specializing in custom viral vectors for gene therapy and cellular therapies. Based in Singapore, the company provides lentiviral vector manufacturing services for preclinical and clinical applications, leveraging proprietary technology to achieve improved yields and process consistency. CellVec serves pharmaceutical and biotech clients developing cell-based immunotherapies and gene therapies for cancer and genetic diseases.
Frequently asked questions
- What types of viral vectors does CellVec manufacture?
- CellVec specializes in custom lentiviral vectors for preclinical and clinical applications. The company has developed a proprietary lentivirus-based vector platform designed to overcome technological bottlenecks in upscale production and deliver improved yields with high process consistency.
- What regulatory certifications and compliance standards does CellVec maintain?
- CellVec is a certified GMP (Good Manufacturing Practice) CDMO with a state-of-the-art facility built to comply with international manufacturing standards. The company is qualified to manufacture viral vectors for both translational research and commercial gene therapy applications.
- What is CellVec's geographic location and regional significance?
- CellVec is based in Singapore and is recognized as Southeast Asia's first GMP-compliant CDMO for viral vector manufacturing. The company has established strategic partnerships with international institutions, including Australia's Peter MacCallum Cancer Centre, to support cell-based immunotherapy development.
- What therapeutic applications does CellVec support?
- CellVec manufactures viral vectors for gene therapies and cellular therapies targeting genetic diseases and cancer. The company specifically supports clients developing cell-based immunotherapies and advanced therapeutic medicinal products (ATMPs).
- What manufacturing challenges does CellVec address?
- CellVec's platform technology is designed to overcome existing bottlenecks in viral vector upscale production, which is characterized as unpredictable, complex, and challenging for traditional biologics manufacturers. The company emphasizes process-driven design and consistency to enable clinical and commercial-scale manufacturing.